NervGen Pharma (NGEN)
NASDAQ:NGEN
Want to see NGEN full AI Analyst Report?
Total Valuation
NervGen Pharma has a market cap or net worth of $303.49M. The enterprise value is $396.61M.
Market Cap$303.49M
Enterprise Value$396.61M
Share Statistics
NervGen Pharma has 80,930,870 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding80,930,870
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NervGen Pharma’s return on equity (ROE) is -12.69 and return on invested capital (ROIC) is -719.57%.
Return on Equity (ROE)-12.69
Return on Assets (ROA)-1.90
Return on Invested Capital (ROIC)-719.57%
Return on Capital Employed (ROCE)-7.21
Revenue Per Employee0.00
Profits Per Employee-4.01M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NervGen Pharma is ―. NervGen Pharma’s PEG ratio is 1.67.
PE Ratio―
PS Ratio0.00
PB Ratio82.04
Price to Fair Value116.50
Price to FCF-12.55
Price to Operating Cash Flow-19.32
PEG Ratio1.67
Income Statement
In the last 12 months, NervGen Pharma had revenue of 0.00 and earned -44.12M in profits. Earnings per share was -0.61.
Revenue0.00
Gross Profit0.00
Operating Income-25.08M
Pretax Income-44.12M
Net Income-44.12M
EBITDA-5.65M
Earnings Per Share (EPS)-0.61
Cash Flow
In the last 12 months, operating cash flow was -19.50M and capital expenditures 0.00, giving a free cash flow of -19.50M billion.
Operating Cash Flow-19.50M
Free Cash Flow-19.50M
Free Cash Flow per Share-0.24
Dividends & Yields
NervGen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change61.33%
50-Day Moving Average4.05
200-Day Moving Average3.50
Relative Strength Index (RSI)49.57
Average Volume (3m)135.64K
Important Dates
NervGen Pharma upcoming earnings date is May 14, 2026, After Close (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 14, 2026
Ex-Dividend Date―
Financial Position
NervGen Pharma as a current ratio of 1.16, with Debt / Equity ratio of 0.24%
Current Ratio1.16
Quick Ratio1.16
Debt to Market Cap0.00
Net Debt to EBITDA3.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NervGen Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NervGen Pharma EV to EBITDA ratio is -67.76, with an EV/FCF ratio of -19.64.
EV to Sales0.00
EV to EBITDA-67.76
EV to Free Cash Flow-19.64
EV to Operating Cash Flow-19.64
Balance Sheet
NervGen Pharma has $22.07M in cash and marketable securities with $33.23K in debt, giving a net cash position of $22.06M billion.
Cash & Marketable Securities$22.07M
Total Debt$33.23K
Net Cash$22.06M
Net Cash Per Share$0.27
Tangible Book Value Per Share$0.04
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NervGen Pharma is $11.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.90
Price Target Upside192.38% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast-67.10%